Medicenna Therapeutics Stock Price, News & Analysis

Medicenna Therapeutics Corp. (OTCQX: MDNAF) is a clinical-stage immunotherapy company focused on the development of Superkines targeting cancer, autoimmune and inflammatory diseases. The company is repeatedly described in its public communications as a developer of novel, highly selective versions of interleukins IL‑2, IL‑4 and IL‑13, as well as first‑in‑class Empowered Superkines. Medicenna’s work centers on engineering cytokine-based therapies designed to modulate the immune system in a more precise way than native cytokines.

Medicenna’s stock trades in the United States under the symbol MDNAF and on the Toronto Stock Exchange under the symbol MDNA. According to multiple company news releases, Medicenna operates as a clinical‑stage organization with programs in various stages of preclinical and clinical development rather than as a commercial-stage pharmaceutical manufacturer.

Core Focus: Superkine-Based Immunotherapies

Across its disclosures, Medicenna describes itself as concentrating on IL‑2, IL‑4 and IL‑13 Superkines and Empowered Superkines. Superkines are characterized in the company’s materials as engineered cytokines with enhanced selectivity or activity. Medicenna’s programs are aimed at treating advanced solid tumors, glioblastoma and other conditions where immune modulation is central.

The company highlights three main assets in its pipeline:

• MDNA11 – a long‑acting IL‑2 Superkine in a Phase 1/2 study (ABILITY‑1) in advanced solid tumors, evaluated as monotherapy and in combination with pembrolizumab (KEYTRUDA).
• MDNA113 – a first‑in‑class, tumor‑anchored and conditionally activated PD‑1 x IL‑2 bifunctional Superkine in preclinical and non‑human primate studies, being advanced toward first‑in‑human evaluation for solid tumors.
• Bizaxofusp (formerly MDNA55) – an IL‑4 Empowered Superkine studied in multiple clinical trials for recurrent glioblastoma (rGBM), with Fast Track and Orphan Drug designations from the FDA and Orphan Drug status from the FDA/EMA, as stated in repeated company descriptions.

MDNA11: Long-Acting IL‑2 Superkine Program

In numerous news releases, Medicenna describes MDNA11 as an intravenously administered, long‑acting, “beta‑enhanced not‑alpha” IL‑2 Superkine. It is specifically engineered to preferentially activate cancer‑killing effector T cells and NK cells while showing minimal or no stimulation of immunosuppressive T regulatory cells (Tregs. The company states that this is achieved by designing MDNA11 with superior affinity toward CD122 (IL‑2 receptor beta) and no binding to CD25 (IL‑2 receptor alpha).

According to the company’s descriptions of MDNA11, these properties are enabled by incorporating seven specific mutations into IL‑2 and genetically fusing it to a recombinant human albumin scaffold. Medicenna explains that albumin’s natural propensity to accumulate in highly vascularized sites, including tumors and tumor‑draining lymph nodes, is intended to improve the pharmacokinetic profile and pharmacological activity of MDNA11.

MDNA11 is being evaluated in the Phase 1/2 ABILITY‑1 study (NCT05086692), a global, multi‑center, open‑label trial assessing safety, tolerability, pharmacokinetics, pharmacodynamics and anti‑tumor activity of MDNA11 as monotherapy and in combination with pembrolizumab in patients with advanced solid tumors. Company updates note that the study includes dose‑escalation and expansion cohorts and that MDNA11 has been tested across a range of solid tumor types, including cohorts enriched for immune checkpoint inhibitor‑resistant cancers such as melanoma, microsatellite instability‑high (MSI‑H) cancers, microsatellite stable (MSS) endometrial cancer and TMB‑high tumors.

Medicenna has reported that MDNA11 has demonstrated a manageable safety profile in the ABILITY‑1 study, with the majority of treatment‑related adverse events described as Grade 1‑2 and transient, and no dose‑limiting toxicities observed at doses up to 120 µg/kg in monotherapy or in combination with pembrolizumab, based on the company’s own summaries. The company also reports that a biological effective dose range (BEDR) of 60–120 µg/kg has been established.

Clinical Development Strategy for MDNA11

Medicenna’s news releases outline a development plan for MDNA11 that spans late‑stage advanced metastatic cancers and earlier‑stage settings. In advanced, treatment‑refractory solid tumors, ABILITY‑1 is designed to assess MDNA11 both alone and with pembrolizumab, including patients who have progressed on prior immune checkpoint inhibitors. Company updates describe deep and durable responses and disease control in multiple tumor types, and note that disease control has been associated with longer overall survival in exploratory analyses.

In addition, Medicenna has announced the NEO‑CYT trial, a randomized, multi‑centre neoadjuvant study sponsored by Fondazione Melanoma Onlus. NEO‑CYT will evaluate MDNA11 in combination with nivolumab, with or without ipilimumab, in patients with high‑risk, surgically resectable Stage III cutaneous melanoma. According to the company’s disclosures, this trial is intended to explore MDNA11 as a neoadjuvant immunotherapy in earlier‑stage melanoma patients, with Major Pathologic Response (MPR) as a primary endpoint, which the company notes is considered predictive of long‑term survival outcomes.

MDNA113: PD‑1 x IL‑2 Bifunctional Superkine

MDNA113 is described by Medicenna as a first‑in‑class, tumor‑anchored and conditionally activated PD‑1 x IL‑2 bifunctional Superkine for solid tumors. The company states that MDNA113 was designed using its proprietary BiSKITs™ (Bifunctional SuperKine ImmunoTherapies) and T‑MASK™ (Targeted Metalloprotease Activated SuperKine) platforms. These platforms are characterized in company materials as approaches to tumor targeting and conditional activation intended to enhance the therapeutic index of Superkines, particularly in immunologically “cold” tumors.

Medicenna reports that MDNA113 is advancing through preclinical and non‑human primate studies. The company has disclosed non‑human primate data indicating that MDNA113 was well tolerated at the highest tested dose, with no untoward clinical findings, lack of C‑reactive protein increase and limited peripheral T cell expansion despite higher dosing compared to a non‑masked version. These findings are presented by the company as supporting the potential for human dosing at levels comparable to standard anti‑PD‑1 therapies.

Across its communications, Medicenna positions MDNA113 as a differentiated PD‑1 x IL‑2 program that combines a targeted anti‑PD‑1 component with an IL‑2 Superkine that has demonstrated single‑agent clinical activity in the MDNA11 program. The company indicates plans to move MDNA113 into IND‑enabling studies and first‑in‑human clinical evaluation.

Bizaxofusp (MDNA55): IL‑4 Empowered Superkine for Glioblastoma

Bizaxofusp, formerly known as MDNA55, is described as an IL‑4 Empowered Superkine that has been studied in five clinical trials enrolling over 130 patients, including a Phase 2b trial for recurrent glioblastoma (rGBM). Company materials characterize rGBM as the most common and uniformly fatal form of brain cancer. Medicenna notes that bizaxofusp has received Fast Track designation from the U.S. FDA and Orphan Drug status from the FDA and EMA.

Medicenna’s recent updates emphasize that the company is pursuing partnership or collaboration opportunities to advance bizaxofusp toward the next stage of development for recurrent GBM and potentially other central nervous system diseases. The company has also highlighted plans to present additional data sets and analyses related to bizaxofusp and IL‑4Rα biology at specialized glioblastoma conferences.

Platform Technologies: BiSKITs™ and T‑MASK™

In addition to individual product candidates, Medicenna repeatedly references its BiSKITs™ and T‑MASK™ platforms. These are described as early‑stage programs designed to enhance the ability of Superkines to treat immunologically “cold” tumors. BiSKITs are presented as bifunctional SuperKine immunotherapies, while T‑MASK is described as a targeted, metalloprotease‑activated SuperKine approach. MDNA113 is cited as an example of a therapy designed using these platforms.

Intellectual Property

Medicenna has reported the issuance and allowance of several patents across multiple jurisdictions, including the United States, Japan, Canada and Australia, relating to IL‑2 Superagonists and IL‑4 fusion formulations. These patents, as described in the company’s news releases, cover uses and methods for IL‑2 Superagonists, agonists and fusions, as well as IL‑4 fusion formulations for treatment of central nervous system tumors, and oncolytic virus targeting of IL‑4/IL‑13 and fusions thereof. Some of these patents are noted as in‑licensed from Stanford University, while others are Medicenna‑owned.

Corporate and Capital Markets Context

Medicenna’s communications indicate that the company is active in capital markets and industry conferences, participating in investor events and healthcare conferences organized by firms and organizations such as ROTH, H.C. Wainwright, BIO‑Europe and other sector‑focused gatherings. The company also reports holding annual shareholder meetings and discloses voting results for its board nominees, which indicates an ongoing public company governance structure.

In its financial updates, Medicenna has provided information on operating costs, research and development expenditures, and cash runway guidance, stating that its cash and equivalents are expected to fund planned activities into at least the middle of a specified calendar year. These disclosures underscore that the company remains in the clinical development and investment phase, with spending focused on expanding clinical trials, advancing preclinical programs and maintaining general and administrative functions.

Industry Classification and Business Model

Based on the provided classification, Medicenna falls under Pharmaceutical Preparation Manufacturing within the broader Manufacturing sector. However, its own descriptions consistently emphasize its role as a clinical‑stage immunotherapy company rather than a commercial manufacturer. The company’s business model, as reflected in its disclosures, centers on research, clinical development, and partnering for its Superkine assets, including MDNA11, MDNA113 and bizaxofusp.

Medicenna’s approach, as described in its public statements, is to develop highly selective cytokine‑based therapies that may be used as monotherapies or in combination with established immune checkpoint inhibitors. The company also highlights collaboration with academic and non‑profit organizations, such as Fondazione Melanoma Onlus, for investigator‑initiated trials like NEO‑CYT.

Use of MDNAF Stock Information

For investors and observers, the MDNAF ticker represents exposure to a company whose value is closely tied to the progress of its clinical programs, regulatory interactions, intellectual property, and partnering activities. Company news releases emphasize that drug development involves a high degree of risk and that early‑stage clinical or preclinical results may not be indicative of later‑stage outcomes or regulatory approval, and they caution readers not to place undue reliance on forward‑looking statements or preliminary scientific data.

Key Takeaways

• Medicenna Therapeutics Corp. is a clinical‑stage immunotherapy company focused on engineered cytokines called Superkines.
• The company’s main programs include MDNA11 (IL‑2 Superkine), MDNA113 (PD‑1 x IL‑2 bifunctional Superkine) and bizaxofusp (IL‑4 Empowered Superkine for recurrent GBM).
• MDNA11 is in a global Phase 1/2 study (ABILITY‑1) for advanced solid tumors and is also being studied in a neoadjuvant setting through the NEO‑CYT trial in high‑risk, resectable Stage III melanoma.
• MDNA113 is advancing through preclinical and non‑human primate studies with the goal of entering human trials for solid tumors.
• Bizaxofusp has been evaluated in multiple clinical trials for recurrent glioblastoma and holds Fast Track and Orphan Drug designations, with partnering efforts underway.
• The company emphasizes proprietary platforms (BiSKITs™ and T‑MASK™) and a growing patent estate supporting its Superkine programs.